Treatment for Olisthesis

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Olisthesis+2 More
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is collecting data on patients who had spinal surgery using a certain device to see how effective it was.

Eligible Conditions
  • Olisthesis
  • Intervertebral Disc Degeneration
  • Retrolisthesis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 6 weeks, 3, 6, 12 and 24 months post operatively

Month 6
Interbody fusion rate
Month 24
To measure how much pain the subject is in according to a pain scale 0-10
Month 24
Functional Impairment
To measure the Quality of Life of the subject according to a set list of questions: Questionnaire SF-12

Trial Safety

Trial Design

0 Treatment Group

30 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 6 weeks, 3, 6, 12 and 24 months post operatively

Who is running the clinical trial?

Viedoc TechnologiesUNKNOWN
Invibio LtdLead Sponsor
8 Previous Clinical Trials
166 Total Patients Enrolled
Keos LLCUNKNOWN
Technomics ResearchIndustry Sponsor
2 Previous Clinical Trials
605 Total Patients Enrolled
Medical Metrics Diagnostics, IncIndustry Sponsor
12 Previous Clinical Trials
1,678 Total Patients Enrolled
Louis A Marotti, M.D. PhDPrincipal InvestigatorNeurosurgical Associates of Lancaster

Eligibility Criteria

Age 18+ · All Participants · 9 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are female and you have not had a pregnancy test in the past 12 months.
You are able to understand the study and to co-operate with the study procedures.
You have to be aged 18 years or older.\n

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 8th, 2021

Last Reviewed: November 26th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.